Antiprotozoal compound derived from coelenterata
The object is to develop an antiprotozoal remedy having a novel mechanism of action. Provided is a compound represented by a chemical formula (1), a prodrug or a pharmaceutically acceptable salt thereof, wherein within the formula (1), R 1 represents R 10 — of formula (4) or R 20 — of formula (5); R 2 represents CHO—, etc.; R 3 represents a hydrogen atom, CH 3 —C(═O)—, etc.; R 4 represents a hydrogen atom, CH 3 —C(═O)—, etc.; each of R 11 and R 12 independently represents a hydrogen atom, a methyl group, etc.; R 13 represents —CH 2 —, —CH(—OH)— or —C(═O)—; each of R 21 and R 22 independently represents a hydrogen atom, a methyl group, etc.; R 23 represents —CH 2 —, —CH(—OH)— or —C(═0)—; and R 24 represents a hydrogen atom, a hydroxyl group, a methyl group, etc.
1. A compound having a structure represented by a chemical formula described below:
2. A pharmaceutical composition for treating a protozoal infection, the composition comprising the compound according to claim 1 .
3. The pharmaceutical composition for treating a protozoal infection according to claim 2 , wherein the protozoal infection is at least one protozoal infection selected from the group consisting of leishmaniasis, trypanosomiasis and malaria.
4. A pharmaceutical composition for treating a protozoal infection, the composition comprising at least one medicine selected from the group consisting of pentavalent antimonials, pentamidine, aminosidine, amphotericin B and liposomal amphotericin B, and the compound according to claim 1 , wherein the at least one medicine and the compound according to claim 1 are administered either simultaneously or sequentially.
5. The pharmaceutical composition for treating a protozoal infection according to claim 4 , wherein the protozoal infection is at least one protozoal infection selected from the group consisting of leishmaniasis, trypanosomiasis and malaria.